News
News +

News

current position:Home>News>News

Shanghai Bocimed will participate in the 76th API China &

Shanghai Bocimed will participate in the 76th API China & PHARMPACK & SINOPHEX & PHARMEX and welcome to visit our company.

READ MORE+

Shanghai Bocimed will participate in the 16th CPHI China

CFDA public comment on the quality In April 11th, the General Administration of food and Drug Administration of the general office of the quality and efficacy of generic drugs to seek consistency evaluation reference preparation for the rec

READ MORE+

Mayne Pharma Receives FDA Approval for Dofetilide Capsules a

First generic approval to Pfizer s US$200m Tikosyn brand Awarded 180-days of market exclusivity as the first company to file a substantially complete ANDA containing a Paragraph IV certification Commercial launch has commenced 7 June 2016,

READ MORE+

Roche receives EU Approval of Avastin in Combination with Ta

First generic approval to Pfizer s US$200m Tikosyn brand Awarded 180-days of market exclusivity as the first company to file a substantially complete ANDA containing a Paragraph IV certification Commercial launch has commenced 7 June 2016,

READ MORE+

ThromboGenics Receives US FDA Approval for New 'Already-Dilu

ThromboGenics Receives US FDA Approval for New Already-Diluted Formulation of JETREA LEUVEN , Belgium , June 8, 2016 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines fo

READ MORE+

Patient-reported outcomes across phase 3 studies of bariciti

Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) Pivotal trials show treatment wi

READ MORE+

Cerulean Announces Manuscript Published in Annals of Oncolog

Data from 22 Evaluable Metastatic Renal Cell Carcinoma Patients Treated with CRLX101 in Combination with Avastin in Phase 1b/2 Investigator-Sponsored Trial Led by University of Pennsylvania WALTHAM, Mass., Jun. 09, 2016 -- ( BUSINESS WIRE )

READ MORE+

Therapy focus – First-line lung cancer is an Opdivo vs Keyt

New data from early studies of checkpoint inhibitors in non-small cell lung cancer emerged at Asco, but none represented the results that the oncology field is awaiting most eagerly. This accolade is reserved for the outcome of the phase III

READ MORE+

  • 18条记录